ALGS · NASDAQ
Average $53.77 (+969.0% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Lake Street | May 28, 2026 | Initiates | Buy |
| Cantor Fitzgerald | May 21, 2026 | Initiates | Overweight |
| WestPark Capital | Mar 26, 2026 | Initiates | Buy |
| Jefferies | Mar 19, 2026 | Initiates | Buy |
| HC Wainwright & Co. | Mar 11, 2026 | Maintains | Buy |
| UBS | Jan 7, 2026 | Initiates | Buy |
Updated Aug 29, 2026
Aligos Therapeutics is positioned for success due to its strong pipeline, promising results for its HBV and MASH drug candidates, and a solid cash position for further development. While there are risks involved, the potential for partnerships and expansion of their studies is encouraging for investors. Overall, the company's positive outlook makes it a strong investment opportunity in the biopharmaceutical sector.
Aligos Therapeutics is facing significant headwinds in the market due to reported concerns about the efficacy and safety of its lead drug candidate, pevifoscorvir sodium (pevi). This therapy, although belonging to a novel class of drugs with potentially higher resistance barriers, has shown only modest response rates in clinical trials, and there are concerns about elevations in liver enzymes and rebound HBV DNA levels after treatment cessation. Additionally, the company has a limited pipeline and is heavily reliant on the success of pevi for its future growth.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
